Canine Melanoma Vaccine
ONCEPT® Canine Melanoma Vaccine aids in extending survival times of dogs with stage II or stage III oral melanoma and for which local disease control has been achieved (negative local lymph nodes or positive lymph nodes that were surgically removed or irradiated).
Efficacy – ONCEPT® Canine Melanoma Vaccine is a safe, effective adjunct therapy that can significantly prolong survival times in dogs with stage I or III Canine Oral Melanoma (COM) for which local disease control has been achieved by traditional means.2
Each dose of ONCEPT® Canine Melanoma Vaccine contains plasmid DNA that expresses the gene coding for human tyrosinase.
Tyrosinase protein is overexpressed on melanoma cells.
Upon injection, the DNA is taken up by muscle cells which then express the human tyrosinase protein.
The human tyrosinase protein is different enough from the canine tyrosinase protein that it will stimulate an immune response, yet similar enough to the canine tyrosinase that the immune response is effective against canine melanoma cells which express tyrosinase.
The vaccine is packaged in a box containing four single-dose vials. This package of four vials is sufficient for the initial series of vaccinations required to treat one dog. Initial treatment requires administration of four doses of vaccine at two week intervals. A booster dose should be administered at six month intervals.
The vaccine is administered in 0.4 mL dose volume using the VET JET® transdermal vaccination system. Refer to the device package insert for instructions on vaccinating with the device. The site of injection for all size dogs is into the muscle of the medial thigh just caudal to the femur.
Safety – There are no known contraindications for the use of this product in dogs with oral melanoma. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions.3
A transient, low-grade fever may be observed in some dogs. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti inflammatories, and/or epinephrine.
Transdermal injection has been associated with injection site pain, swelling, and bruising. Please see device label for complete information.
There are no known contraindications
Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006;24(21):4582-4585.
Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011;72(12):1631-1638.
ONCEPT® [Product Label]. Duluth, GA: Boehringer Ingelheim Animal Health USA Inc.; 2012.
ONCEPT® and VET JET® are registered trademarks and BI-CONNECT™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.